Search research articles
Contact Us
Filters
Showing results (11-20 of 541) with videos related to
Page
of 55
Sort By:
Circulation
|
November 20, 2014
Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west
Patrick Rossignol, Faiez Zannad
Expert Opinion on Drug Safety
|
March 10, 2016
The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure
Bertram Pitt, Patrick Rossignol
American Journal of Hypertension
|
July 31, 2018
Relation of Serum Potassium to Cardiovascular Events in Patients With Heart Failure and Preserved Ejection Fraction: "Mind the Gap"
Bertram Pitt, Patrick Rossignol
Journal of the American Heart Association
|
December 25, 2017
Mineralocorticoid Receptor Antagonists in High-Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease
Bertram Pitt, Patrick Rossignol
La Revue Du Praticien
|
October 18, 2008
[Methodology of clinical research]
François Alla, Patrick Rossignol
European Journal of Heart Failure
|
February 16, 2023
Mineralocorticoid receptor antagonist use in renal dialysis: will evidence from prospective randomized trials confirm the results from 'real-world' evidence?
Patrick Rossignol, Bertram Pitt
The New England Journal of Medicine
|
June 4, 2020
Cardiovascular Consequences of Acute Kidney Injury
Matthieu Legrand, Patrick Rossignol
Clinical Kidney Journal
|
August 2, 2023
Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: <i>primum non nocere</i>!
Patrick Rossignol, Bertram Pitt
JAMA Internal Medicine
|
November 3, 2015
Measurement Methodology: What Does Blood Pressure Mean in the PARTAGE Study?-Reply
Athanase Benetos, Patrick Rossignol
Circulation
|
May 10, 2017
Cardiovascular Outcome Trials in Patients With Advanced Kidney Disease: Time for Action
Faiez Zannad, Patrick Rossignol
Page
of 55
Search research articles
Search
Showing results (11-20 of 541) with videos related to
Sort By:
Page
of 55
Circulation
|
November 20, 2014
Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west
Patrick Rossignol, Faiez Zannad
Expert Opinion on Drug Safety
|
March 10, 2016
The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure
Bertram Pitt, Patrick Rossignol
American Journal of Hypertension
|
July 31, 2018
Relation of Serum Potassium to Cardiovascular Events in Patients With Heart Failure and Preserved Ejection Fraction: "Mind the Gap"
Bertram Pitt, Patrick Rossignol
Journal of the American Heart Association
|
December 25, 2017
Mineralocorticoid Receptor Antagonists in High-Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease
Bertram Pitt, Patrick Rossignol
La Revue Du Praticien
|
October 18, 2008
[Methodology of clinical research]
François Alla, Patrick Rossignol
European Journal of Heart Failure
|
February 16, 2023
Mineralocorticoid receptor antagonist use in renal dialysis: will evidence from prospective randomized trials confirm the results from 'real-world' evidence?
Patrick Rossignol, Bertram Pitt
The New England Journal of Medicine
|
June 4, 2020
Cardiovascular Consequences of Acute Kidney Injury
Matthieu Legrand, Patrick Rossignol
Clinical Kidney Journal
|
August 2, 2023
Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: <i>primum non nocere</i>!
Patrick Rossignol, Bertram Pitt
JAMA Internal Medicine
|
November 3, 2015
Measurement Methodology: What Does Blood Pressure Mean in the PARTAGE Study?-Reply
Athanase Benetos, Patrick Rossignol
Circulation
|
May 10, 2017
Cardiovascular Outcome Trials in Patients With Advanced Kidney Disease: Time for Action
Faiez Zannad, Patrick Rossignol
Page
of 55